We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00608634
First Posted: February 6, 2008
Last Update Posted: April 1, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Cancer Institute (NCI)
Arizona Disease Control Research Commission
Information provided by (Responsible Party):
University of Arizona
Results First Submitted: April 15, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Precancerous Condition
Interventions: Drug: perillyl alcohol
Other: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placbeo Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
Low Dose POH 0.30% Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
High Dose POH 0.76% Patients apply POH cream (0.76%) as in arm II.

Participant Flow:   Overall Study
    Placbeo   Low Dose POH 0.30%   High Dose POH 0.76%
STARTED   28   27   28 
COMPLETED   26   26   27 
NOT COMPLETED   2   1   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Arm I Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
Arm II Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
Arm III Patients apply POH cream (0.76%) as in arm II.
Total Total of all reporting groups

Baseline Measures
   Arm I   Arm II   Arm III   Total 
Overall Participants Analyzed 
[Units: Participants]
 28   27   28   83 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   14   10   13   37 
>=65 years   14   17   15   46 
Age 
[Units: Years]
Mean (Standard Deviation)
 66.9  (9.9)   68.8  (10.6)   67.6  (10.9)   67.7  (10.4) 
Gender 
[Units: Participants]
       
Female   8   7   5   20 
Male   20   20   23   63 
Region of Enrollment 
[Units: Participants]
       
United States   28   27   28   83 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Histopathology Score of Sun Damaged Skin by Treatment Group   [ Time Frame: Baseline to 3 months ]

2.  Secondary:   Skin Related Events From Perillyl Alcohol at Administered Doses by Participants   [ Time Frame: 3 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Steven P. Stratton, PhD
Organization: Arizona Cancer Center
phone: 520-626-9295
e-mail: sstratton@azcc.arizona.edu



Responsible Party: University of Arizona
ClinicalTrials.gov Identifier: NCT00608634     History of Changes
Other Study ID Numbers: CDR0000582634
P01CA027502 ( U.S. NIH Grant/Contract )
P30CA023074 ( U.S. NIH Grant/Contract )
UARIZ-HSC-04-27 ( Other Identifier: UA IRB no. )
UARIZ-POH-002 ( Other Identifier: NCI )
First Submitted: February 5, 2008
First Posted: February 6, 2008
Results First Submitted: April 15, 2011
Results First Posted: April 1, 2015
Last Update Posted: April 1, 2015